Age‐related features of lung cancer treatment using reprogrammed CD8 positive T cells in mice subjected to injection of Lewis lung carcinoma cells

Author:

Skurikhin Evgenii1ORCID,Zhukova Mariia1,Ermakova Natalia1,Pan Edgar1ORCID,Widera Darius2,Sandrikina Lubov3,Kogai Lena34,Kushlinskii Nikolai5,Kubatiev Aslan1,Morozov Sergey1,Dygai Alexander13

Affiliation:

1. Institute of General Pathology and Pathophysiology Moscow Russia

2. Stem Cell Biology and Regenerative Medicine Group School of Pharmacy, Whiteknights Campus Reading UK

3. Goldberg ED Research Institute of Pharmacology and Regenerative Medicine Tomsk National Research Medical Centre of the Russian Academy of Sciences Tomsk Russia

4. Ministry of Health of the Russian Federation Siberian State Medical University Tomsk Russia

5. Blokhin National Medical Research Center of Oncology Moscow Russia

Abstract

AbstractBackgroundAwareness of age‐related features of carcinogenesis and the importance of cellular immunity is crucial for developing effective antitumor therapies for specific patient groups.MethodsIn this study, we examined different populations of cancer stem cells (CSCs) and circulating tumor cells (CTCs) in "young" (8‐10 weeks) and "aged" (80‐82 weeks) C57BL/6 male mice. We used an orthotopic model of Lewis lung carcinoma (LLC) to evaluate the effectiveness of cell therapy targeting lung cancer through reprogrammed CD8‐positive T cells (rCD8+ T cells) in mice from two different ages.ResultsThe findings revealed that tumor progression with age is primarily caused by impaired recruitment of T cells to the lungs. Additionally, a lower number of CTCs and CSCs were observed in younger mice compared to the older mice. The antitumor effect of rCD8+ T cells in aged mice was found to be inferior to that in young mice, which can be attributed to the reduced impact of therapy on specific CSCs populations.ConclusionsThese results offer new insights into the treatment of lung cancer using rCD8+ T cells. Considering the age‐related characteristics influencing disease progression, this therapy has the potential to significantly enhance the effectiveness of treatment methods.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3